• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 5:15:50 PM ET
    $EARS
    Major Pharmaceuticals
    Health Care
    Get the next $EARS alert in real time by email
    SC 13G/A 1 ears-sc13ga_123120.htm AMENDMENT TO FORM SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 2) *

    Auris Medical Holding Ltd.

    (Name of Issuer)

     

    Common Shares, par value CHF 0.01 per share

    (Title of Class of Securities)

     

    G07025201

    (CUSIP Number)

     

    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      ☐ Rule 13d-1(b)
         
      ☒ Rule 13d-1(c)
         
      ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

       
     

     

    CUSIP No . G07025201   Page 2 of 8

     

    1

    NAME OF REPORTING PERSONS
    Altium Capital Management, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2066653

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    0

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    0

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     
    12

    TYPE OF REPORTING PERSON

    IA, PN

     
             

     

       
     

     

    CUSIP No . G07025201   Page 3 of 8

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth Fund, LP

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2105101

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    0

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    0

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     
    12

    TYPE OF REPORTING PERSON

    PN

     
             

     

       
     

     

     

    CUSIP No . G07025201   Page 4 of 8

     

    1

    NAME OF REPORTING PERSONS
    Altium Growth GP, LLC

     

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
    (ENTITIES ONLY) EIN: 82-2086430

     
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☐

    (b) ☒

    3 SEC USE ONLY  
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware, United States of America

     

    NUMBER OF
    SHARES

    BENEFICIALLY
    OWNED BY

    EACH
    REPORTING

    PERSON
    WITH:

    5

    SOLE VOTING

    0

     
    6

    SHARED VOTING POWER

    0

     
    7

    SOLE DISPOSITIVE POWER

    0

     
    8

    SHARED DISPOSITIVE POWER

    0

     
    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    0%

     
    12

    TYPE OF REPORTING PERSON

    OO

     
             

     

     

     

    CUSIP No. G07025201   Page 5 of 8

     

    Item 1(a). Name of Issuer:                                                          Auris Medical Holding Ltd. (the “Issuer”)
       
       
       
    Item 1(b).

    Address of Issuer’s Principal Executive Offices:  

    4902 Clarendon House, 2 Church Street,

        Hamilton HM 11, Bermuda

     

    Item 2(a).

    Name of Person Filing:

    This statement is jointly filed by and on behalf of each of Altium Growth Fund, LP, Altium Capital Management, LP, and Altium Growth GP, LLC. Altium Growth Fund, LP is the record and direct beneficial owner of the securities covered by this statement. Altium Capital Management, LP is the investment adviser of, and may be deemed to beneficially own securities, owned by, Altium Growth Fund, LP. Altium Growth GP, LLC is the general partner of, and may be deemed to beneficially own securities owned by, Altium Growth Fund, LP.

     

    Each reporting person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each of the reporting persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the reporting persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
      The address of the principal business office of each of the reporting persons is
    152 West 57 Street, FL 20, New York, NY 10019
       
    Item 2(c). Citizenship:
      See Item 4 on the cover page(s) hereto.
       
    Item 2(d). Title of Class of Securities:
      Common Shares, par value CHF 0.01 per share
       
    Item 2(e). CUSIP Number: G07025201
       

    Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
       
      (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

       
     

     

    CUSIP No. G07025201   Page 6 of 8

     

      (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(ii)(G);
           
      (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).
           
    Item 4. Ownership.
       
      As of the close of business on December 31, 2020, each of the Reporting Persons have no beneficial ownership of the Issuer’s Common Stock.

     

     

       
     

     

    CUSIP No . G07025201   Page 7 of 8

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  ☒
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
      Not applicable
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable
       
       
    Item 8. Identification and Classification of Members of the Group.
      Not applicable
       
       
    Item 9. Notice of Dissolution of Group.
      Not applicable
       
       
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 

      Dated: February 10, 2021
         
      Altium Capital Management, LP
         
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb
      Title: CEO
         
      Altium Growth Fund, LP
       
      By: Altium Growth GP, LLC
      Its: General Partner
         
      Signature: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb
      Title: Managing Member of Altium Growth GP, LLC
         
      Altium Growth GP, LLC
         
      By: /s/ Jacob Gottlieb  
      Name: Jacob Gottlieb
      Title: Managing Member

     

       
     

     

      Page 8 of 8

     

     

    EXHIBIT INDEX

     

     

    EXHIBIT 1: Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
       
      Members of Group

     

     

       
     

     

    Get the next $EARS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EARS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EARS
    SEC Filings

    View All

    SEC Form 6-K filed by Auris Medical Holding Ltd.

    6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)

    9/8/21 9:01:22 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Auris Medical Holding Ltd.

    6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

    7/23/21 4:09:40 PM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Auris Medical Holding Ltd.

    6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

    6/16/21 8:00:32 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    $EARS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

    Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it sign

    7/14/21 9:00:00 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

    Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission in late 2022 Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform. The Company intends to develop the treatment under project code AM-401 with submission of an IND tar

    7/6/21 9:00:00 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany

    Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries. "Following the intense and concerted efforts by our team and e

    6/28/21 8:30:00 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    $EARS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Auris Medical Holding Ltd. (Amendment)

    SC 13D/A - Auris Medical Holding Ltd. (0001601936) (Subject)

    5/21/21 7:31:15 AM ET
    $EARS
    Major Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Auris Medical Holding Ltd. (0001601936) (Subject)

    2/12/21 5:15:50 PM ET
    $EARS
    Major Pharmaceuticals
    Health Care